mifepristone has been researched along with Weight Gain in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hunt, H; Koorneef, LL; Kroon, J; Meijer, OC; Mol, IM; Rensen, PCN; Sips, HCM; van de Velde, NM; van den Heuvel, JK; Verzijl, CRC | 1 |
| Howland, RH | 1 |
| Alexander-Chacko, J; Barr, RJ; Carson, MW; Coghlan, M; Gehlert, DR; Morin, M; Need, A; Shaw, J; Sindelar, DK | 1 |
| Antelmi, A; Armani, A; Caprio, M; Chlopicki, S; Cinti, F; Fabbri, A; Feraco, A; Hunt, H; Mammi, C; Marzolla, V; Maslak, E | 1 |
| Allen, K; Belanoff, JK; Blasey, CM; Block, TS; Gross, C; Roe, RL | 1 |
| Belanoff, JK; Blasey, CM; Gross, C; Roe, RL | 1 |
| Beebe, KL; Belanoff, JK; Blasey, C; Block, T; Debattista, C | 1 |
| Baram, TZ; Yi, SJ | 1 |
| Fraser, R; Holloway, CD; Kenyon, CJ; Panarelli, M; Soro, A | 1 |
| Draghia-Akli, R; Ellis, KM; Hill, LA; Malone, PB; Nordstrom, JL; Schwartz, RJ | 1 |
| Anderson, TL; Baulieu, EE; Hodgen, GD; Sinosich, M; Ulmann, A; Wolf, JP | 1 |
1 review(s) available for mifepristone and Weight Gain
| Article | Year |
|---|---|
Mifepristone as a therapeutic agent in psychiatry.
Topics: Affective Disorders, Psychotic; Alcoholism; Antipsychotic Agents; Clinical Trials as Topic; Cocaine-Related Disorders; Hormone Antagonists; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Mental Disorders; Mifepristone; Pituitary-Adrenal System; Psychotic Disorders; Stress Disorders, Post-Traumatic; Weight Gain | 2013 |
2 trial(s) available for mifepristone and Weight Gain
| Article | Year |
|---|---|
Mifepristone treatment of olanzapine-induced weight gain in healthy men.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weights and Measures; Double-Blind Method; Hormone Antagonists; Humans; Insulin; Lipids; Male; Mifepristone; Olanzapine; Weight Gain; Young Adult | 2009 |
Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Double-Blind Method; Hormone Antagonists; Humans; Hypothalamo-Hypophyseal System; Insulin; Male; Metabolic Syndrome; Mifepristone; Pituitary-Adrenal System; Receptors, Glucocorticoid; Reference Values; Risperidone; Triglycerides; Waist Circumference; Weight Gain; Young Adult | 2010 |
8 other study(ies) available for mifepristone and Weight Gain
| Article | Year |
|---|---|
Selective Glucocorticoid Receptor Antagonist CORT125281 Activates Brown Adipose Tissue and Alters Lipid Distribution in Male Mice.
Topics: Adipocytes, Brown; Adiposity; Adrenal Glands; Animals; Anti-Obesity Agents; Cells, Cultured; Corticosterone; Dose-Response Relationship, Drug; HEK293 Cells; Hormone Antagonists; Humans; Lipid Metabolism; Liver; Male; Mice, Inbred C57BL; Mifepristone; Obesity; Organ Size; Receptors, Glucocorticoid; Recombinant Proteins; Weight Gain | 2018 |
LLY-2707, a novel nonsteroidal glucocorticoid antagonist that reduces atypical antipsychotic-associated weight gain in rats.
Topics: Animals; Antipsychotic Agents; Aza Compounds; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; Female; HEK293 Cells; Heterocyclic Compounds, 4 or More Rings; Humans; Indoles; Male; Mice; Mice, Inbred C57BL; Mifepristone; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Glucocorticoid; Sulfonamides; Weight Gain; Weight Loss | 2014 |
A novel combined glucocorticoid-mineralocorticoid receptor selective modulator markedly prevents weight gain and fat mass expansion in mice fed a high-fat diet.
Topics: Adipose Tissue; Animals; Diet, High-Fat; Disease Models, Animal; Female; Male; Mice; Mice, Inbred C57BL; Mifepristone; Mineralocorticoid Receptor Antagonists; Receptors, Glucocorticoid; Thymine; Weight Gain | 2016 |
The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats.
Topics: Abdominal Fat; Analysis of Variance; Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Dose-Response Relationship, Drug; Drug Interactions; Female; Hormone Antagonists; Mifepristone; Olanzapine; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Glucocorticoid; Receptors, Progesterone; Weight Gain | 2006 |
Methods for implanting steroid-containing cannulae into the paraventricular nucleus of neonatal rats.
Topics: Animals; Animals, Newborn; Catheterization; Cholesterol; Corticotropin-Releasing Hormone; Female; Gene Expression; Mifepristone; Paraventricular Hypothalamic Nucleus; Pregnancy; Rats; Rats, Sprague-Dawley; Weight Gain | 1993 |
Effects of the glucocorticoid antagonist RU486 in spontaneously hypertensive and Sprague Dawley rats.
Topics: Adrenal Glands; Animals; Blood Pressure; Corticosterone; Dexamethasone; Glucocorticoids; Growth; Hormone Antagonists; Male; Mifepristone; Organ Size; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Receptors, Glucocorticoid; Thymus Gland; Weight Gain | 1995 |
Enhanced animal growth via ligand-regulated GHRH myogenic-injectable vectors.
Topics: Animals; Body Composition; Bone Density; Cells, Cultured; Chickens; Genetic Therapy; Genetic Vectors; Growth Hormone-Releasing Hormone; Injections; Insulin-Like Growth Factor I; Kinetics; Ligands; Mice; Mice, SCID; Mifepristone; Muscle, Skeletal; Plasmids; Protein Engineering; Transcriptional Activation; Weight Gain | 2002 |
Progesterone antagonist (RU 486) for cervical dilation, labor induction, and delivery in monkeys: effectiveness in combination with oxytocin.
Topics: Animals; Cervix Uteri; Colostrum; Drug Therapy, Combination; Estrenes; Female; Immunoglobulins; Labor, Induced; Lactation; Macaca fascicularis; Mifepristone; Oxytocin; Pregnancy; Progesterone; Weight Gain | 1989 |